A British biotechnology company developing psilocybin-based therapies for mental health conditions, best known for its investigational drug COMP360, a synthetic form of psilocybin given alongside psychological support. It was founded in 2016 by George Goldsmith, Ekaterina Malievskaia, and Lars Christian Wilde, who were inspired after struggling to find effective treatment for a family member's treatment-resistant mental illness. The name reflects the founders' aim to give patients a "compass" to navigate the mental health system, and it was the first psychedelic-medicine company to list on the NASDAQ.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -7.13M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.